Fluoxetine in social phobia: A double-blind, placebo-controlled pilot study

Kenneth A. Kobak, John H. Greist, James W. Jefferson, David J Katzelnick

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The objective of the study was to examine the efficacy of fluoxetine in social phobia. Sixty subjects were randomly assigned to 14 weeks of double-blind therapy with either fluoxetine or placebo. Dose was fixed at 20 mg for fluoxetine during the first 8 weeks of double-blind treatment; during the final 6 weeks, the dose could be increased every two weeks by 20 mg to a maximum of 60 mg/day. An intentto-treat analysis was used. A significant change from baseline to endpoint was found for both fluoxetine and placebo on the Liebowitz Social Anxiety Scale. However, no significant difference was found between fluoxetine and placebo. The change for fluoxetine was somewhat lower than that found with other selective serotonin reuptake inhibitors, whereas the placebo response was greater. Fluoxetine failed to separate from placebo in this trial. It is unknown whether a larger dose for longer duration would have yielded separation from placebo. A higher than usual placebo response rate was found.

Original languageEnglish (US)
Pages (from-to)257-262
Number of pages6
JournalJournal of Clinical Psychopharmacology
Volume22
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Fluoxetine
Placebos
Serotonin Uptake Inhibitors
Social Phobia
Anxiety
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fluoxetine in social phobia : A double-blind, placebo-controlled pilot study. / Kobak, Kenneth A.; Greist, John H.; Jefferson, James W.; Katzelnick, David J.

In: Journal of Clinical Psychopharmacology, Vol. 22, No. 3, 2002, p. 257-262.

Research output: Contribution to journalArticle

Kobak, Kenneth A. ; Greist, John H. ; Jefferson, James W. ; Katzelnick, David J. / Fluoxetine in social phobia : A double-blind, placebo-controlled pilot study. In: Journal of Clinical Psychopharmacology. 2002 ; Vol. 22, No. 3. pp. 257-262.
@article{02ee37892bf2450e9bdbee5e17520f20,
title = "Fluoxetine in social phobia: A double-blind, placebo-controlled pilot study",
abstract = "The objective of the study was to examine the efficacy of fluoxetine in social phobia. Sixty subjects were randomly assigned to 14 weeks of double-blind therapy with either fluoxetine or placebo. Dose was fixed at 20 mg for fluoxetine during the first 8 weeks of double-blind treatment; during the final 6 weeks, the dose could be increased every two weeks by 20 mg to a maximum of 60 mg/day. An intentto-treat analysis was used. A significant change from baseline to endpoint was found for both fluoxetine and placebo on the Liebowitz Social Anxiety Scale. However, no significant difference was found between fluoxetine and placebo. The change for fluoxetine was somewhat lower than that found with other selective serotonin reuptake inhibitors, whereas the placebo response was greater. Fluoxetine failed to separate from placebo in this trial. It is unknown whether a larger dose for longer duration would have yielded separation from placebo. A higher than usual placebo response rate was found.",
author = "Kobak, {Kenneth A.} and Greist, {John H.} and Jefferson, {James W.} and Katzelnick, {David J}",
year = "2002",
doi = "10.1097/00004714-200206000-00005",
language = "English (US)",
volume = "22",
pages = "257--262",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Fluoxetine in social phobia

T2 - A double-blind, placebo-controlled pilot study

AU - Kobak, Kenneth A.

AU - Greist, John H.

AU - Jefferson, James W.

AU - Katzelnick, David J

PY - 2002

Y1 - 2002

N2 - The objective of the study was to examine the efficacy of fluoxetine in social phobia. Sixty subjects were randomly assigned to 14 weeks of double-blind therapy with either fluoxetine or placebo. Dose was fixed at 20 mg for fluoxetine during the first 8 weeks of double-blind treatment; during the final 6 weeks, the dose could be increased every two weeks by 20 mg to a maximum of 60 mg/day. An intentto-treat analysis was used. A significant change from baseline to endpoint was found for both fluoxetine and placebo on the Liebowitz Social Anxiety Scale. However, no significant difference was found between fluoxetine and placebo. The change for fluoxetine was somewhat lower than that found with other selective serotonin reuptake inhibitors, whereas the placebo response was greater. Fluoxetine failed to separate from placebo in this trial. It is unknown whether a larger dose for longer duration would have yielded separation from placebo. A higher than usual placebo response rate was found.

AB - The objective of the study was to examine the efficacy of fluoxetine in social phobia. Sixty subjects were randomly assigned to 14 weeks of double-blind therapy with either fluoxetine or placebo. Dose was fixed at 20 mg for fluoxetine during the first 8 weeks of double-blind treatment; during the final 6 weeks, the dose could be increased every two weeks by 20 mg to a maximum of 60 mg/day. An intentto-treat analysis was used. A significant change from baseline to endpoint was found for both fluoxetine and placebo on the Liebowitz Social Anxiety Scale. However, no significant difference was found between fluoxetine and placebo. The change for fluoxetine was somewhat lower than that found with other selective serotonin reuptake inhibitors, whereas the placebo response was greater. Fluoxetine failed to separate from placebo in this trial. It is unknown whether a larger dose for longer duration would have yielded separation from placebo. A higher than usual placebo response rate was found.

UR - http://www.scopus.com/inward/record.url?scp=0036113828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036113828&partnerID=8YFLogxK

U2 - 10.1097/00004714-200206000-00005

DO - 10.1097/00004714-200206000-00005

M3 - Article

C2 - 12006895

AN - SCOPUS:0036113828

VL - 22

SP - 257

EP - 262

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 3

ER -